A Fibronectin (FN)‐Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis
Small · 2026
DOI: 10.1002/smll.202409126 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2026. Verfasst von Sarah Teworte und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Technology Research Group, Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freiestrasse 3, Bern…. Hauptthemen laut MEDLINE: Endometriosis, Fibronectins, Silk, Drug Repositioning. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss National Science Foundation, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
This study advances sustainable pharmaceutical research for endometriosis by developing in vitro 3D cell culture models of endometriotic pathophysiology that allow antifibrotic drug candidates to be tested. Fibrosis is a key aspect of endometriosis, yet current cell models to study it remain limited. This work aims to bridge the translational gap between in vitro fibrosis research and preclinical testing of non‐hormonal drug candidates. When grown in a 3D matrix of sustainably produced silk protein functionalized with a fibronectin‐derived cell adhesion motif (FN‐silk), endometrial stromal and epithelial cells respond to transforming growth factor beta‐1 (TGF‐β1) in a physiological manner as probed at the messenger RNA (mRNA) level. For stromal cells, this response to TGF‐β1 is not observed in spheroids, while epithelial cell spheroids behave similarly to epithelial cell FN‐silk networks. Pirfenidone, an antifibrotic drug approved for the treatment of idiopathic pulmonary fibrosis, reverses TGF‐β1‐induced upregulation of mRNA transcripts involved in fibroblast‐to‐myofibroblast transdifferentiation of endometrial stromal cells in FN‐silk networks, supporting pirfenidone's potential as a repurposed non‐hormonal endometriosis therapy. Overall, endometrial stromal cells cultured in FN‐silk networks—which are composed of a sustainably produced, fully defined FN‐silk protein—recapitulate fibrotic cellular behavior with high fidelity and enable antifibrotic drug testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Technology Research Group, Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freiestrasse 3, Bern, CH-3012, Switzerland.
- Division of Protein Technology, School of Biotechnology, KTH Royal Institute of Technology, AlbaNova University Center, Stockholm, SE-106 91, Sweden.
- RNA Biology Research Group, Department of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, Freiestrasse 3, Bern, CH-3012, Switzerland.
ORCID-Profile: Sarah Teworte, Mark C Behrens, Mona Widhe, Lukas-Adrian Gurzeler, My Hedhammar, Paola Luciani
Förderung
- Swiss National Science Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Teworte, S., Behrens, M. C., Widhe, M., Gurzeler, L. A., Hedhammar, M., & Luciani, P. (2026). A Fibronectin (FN)‐Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis. Small. https://doi.org/10.1002/smll.202409126
Vancouver
Teworte S, Behrens MC, Widhe M, Gurzeler LA, Hedhammar M, Luciani P. A Fibronectin (FN)‐Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis. Small. 2026. doi:10.1002/smll.202409126
BibTeX
@article{Teworte2026,
author = {Teworte, Sarah and Behrens, Mark C and Widhe, Mona and Gurzeler, Lukas-Adrian and Hedhammar, My and Luciani, Paola},
title = {A Fibronectin (FN)‐Silk 3D Cell Culture Model as a Screening Tool for Repurposed Antifibrotic Drug Candidates for Endometriosis},
journal = {Small},
year = {2026},
doi = {10.1002/smll.202409126}
}
EUVIMED